Report LibraryAll Reports
Datamonitor Healthcare Oncology: Prostate Cancer Disease Coverage
Retail Price: $22,000.00*BioMedTracker Subscriber Price: $15,000.00 - click here to log in
June 01, 2018Prostate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to its large population size. While hormone-sensitive prostate cancer is well managed in terms of treatment options, unmet need persists for patients with prostate cancer that is no longer responsive to hormonal manipulation. Newly approved therapies for castration-resistant prostate cancer are set to create a shift in the way that the disease is treated, while creating a competitive environment for new market entrants.
This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, Pricing & Reimbursement, and Pipeline modules.
|Disease Group Covered:||Oncology|